Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
151-165 of 51311 results
Synpromics to partner with Lonza to improve biopharmaceuticals manufacturing
Synpromics has partnered with Lonza Pharma & Biotech to further develop its inducible promoter system and enhance manufacturing of biopharmaceuticals.
Production & Manufacturing > Manufacturing > News
Fresenius Kabi scraps $4.3bn merger with US generic drugmaker Akorn
By PBR Staff Writer
Germany-based Fresenius Kabi has scrapped its $4.3bn merger agreement with Akorn, saying that the US generic drugmaker did not fulfill various closing conditions.
Production & Manufacturing > Manufacturing > News
Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Contract Research & Services > Clinical Trials > News
Tmunity raises another $35m to advance T Cell therapies
Tmunity Therapeutics, a biotherapeutics company focused on developing next-generation T cell immunotherapy, has raised new funding of $35m in a Series A investment from Kleiner Perkins and affiliates.
Drug Research > Drug Discovery & Development > News
Shire rejects $63bn takeover proposal from Takeda
By PBR Staff Writer
Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline.
Drug Research > Drug Discovery & Development > News
BenevolentAI raises $115m to advance AI-enabled drug development activities
By PBR Staff Writer
BenevolentAI has secured $115m funding to advance drug development activities and extend its artificial intelligence (AI) platform capabilities.
Drug Research > Drug Discovery & Development > News
FDA approves Tagrisso as first-line treatment for EGFR-mutated non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) as the first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations.
Regulatory Affairs > News
Sandoz, Pear to commercialize prescription digital therapeutics
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Drug Research > Drug Discovery & Development > News
Merck to sell global consumer health business to P&G for $4.2bn
By PBR Staff Writer
Merck has agreed to sell its global consumer health business to Procter & Gamble (P&G) for about €3.4bn ($4.2bn).
News
Roche’s Hemlibra gets FDA breakthrough status in haemophilia A without inhibitors
By PBR Staff Writer
Roche has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Hemlibra (emicizumab) to treat people with haemophilia A without factor VIII inhibitors.
Regulatory Affairs > News
Catabasis Pharmaceuticals to reduce workforce by about 42%
Catabasis Pharmaceuticals is restructuring its resources to focus on late-stage lead program, edasalonexent, for the treatment of Duchenne muscular dystrophy (DMD).
Drug Research > Drug Discovery & Development > News
Novartis to invest $100m into antimalarials research
Novartis said that it will invest more than $100m to advance research and development of new antimalarials over the next five years.
Drug Research > Drug Discovery & Development > News
Advent in talks to buy Sanofi’s European generics business for EUR1.9bn
By PBR Staff Writer
US-based global private equity firm Advent International has entered into exclusive talks to acquire Sanofi’s European generics business, Zentiva, for €1.9bn.
News
Alliance Pharma to divest 60% stake in Unigreg
Alliance Pharma's subsidiary Alliance Pharmaceuticals has agreed to sell its 60% interest in non-core Unigreg to its joint venture partner Pacific Glory Development for a consideration of £2.9m.
Production & Manufacturing > Manufacturing > News
Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease
Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.
Contract Research & Services > Clinical Trials > News
151-165 of 51311 results